drugset / Trial / NCT05023577
Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized controlled clinical trial will compare the eradication efficacy of bismuth quadruple therapy containing clarithromycin+metronidazole, clarithromycin+levofloxacin, or metronidazole+levofloxacin for Helicobacter pylori first-line treatment in penicillin-allergic patients. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.
Timeline
- Start
- 2021-08-26
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 0.5 g | — |
| Subject | Levofloxacin | Small molecule | 0.5 g | — |
| Subject | Metronidazole | Small molecule | 0.4 g | — |
| Background | Bismuth Potassium Citrate | Unknown | 0.6 g | — |
| Background | Rabeprazole | Small molecule | 20 mg | — |